I-FDA-Iyavunyelwa i-Spondyloarthropathie ethile kunye ne-Plaque Psoriasis
I-Cosentyx (secukinumab), eyenziwe nguNovartis, yavunywa yi-FDA ngoJanuwari 15, 2016 ukwenzela unyango lwabantu abadala abane- spondylitis esebenzayo kunye ne- psoriatic arthritis esebenzayo. Kwaye sele ivunyiwe ngoJanuwari 2015 ukuba i-modori ye- plaque ye-psoriasis eqinile kubantu abadala abaviwa bezocwangciso zonyango okanye i-phototherapy. I-ankylosing spondylitis kunye ne-psoriatic arthritis ziintlobo zokuvuvukala kwe-arthritis ezichazwe njenge- spondyloarthropathies .
Ukuvunyelwa kweCosentyx kwi-spondylitis ne-psoriatic ye-arthritis eyayisisigxina esekelwe kwiziphumo ezivela kwi-spondylitis e-2 engavumelwaneni kunye ne-psoriatic ye-arthritis ye-phasebo elawulwa yi-phase-III yezilingo ezinokuhlolwa kovavanyo kunye nokusebenza. Izilingo zabandakanya abantu abangaphezu kwe-1,500 ababenomnye weemeko ezimbini.
Yintoni i-Cosentyx?
I-Cosentyx yipilisi esebenza kwi- immune system ukuphatha izifo kunye nezimo ezikhankanywe ngasentla. Ngokukodwa, i-Cosentyx ngumntu oyisigxina se-interleukin-17A (IL-17A) -i- anti-monoplonal antibody ebopha kwi-IL-17A kwaye ibingene ukusebenzisana ne-IL-17 receptor. Nguyena owayengumdlali we-interleukin-17A ovumile ukuba aphathe i-spondylitis ye-ankylosing, i-psoriatic arthritis kunye ne-psqueasis ye-plaque.
Ilawulwa Ngayo Imithi?
I-Cosentyx ilawulwa yi-injection engaphantsi kwinqaba eliphezulu okanye isisu. I-Cosentyx ifumaneka njengesisombululo se-injection (150 mg / mL) kwisinye se-Sensoready ipeni.
Kukwafumaneka kwakhona kwisirinji esetyenziswayo esisodwa (150 mg / mL). Kukho i-vial emele ibuyiswe kwakhona kwakhona, kodwa yile yabasebenzi bezempilo kuphela.
Kwabantu abane-arthritis esebenzayo ye-psoriatic okanye i-spondylitis e-ankylosing, i-dose ephakanyisiweyo ye-Cosentyx ibandakanya umthamo wokulayisha we-150 mg kwiiveki 0, 1, 2, 3 no-4, zilandelwa ziiveki ezine.
Inokunikezelwa rhoqo kwiiveki ezi-4 ngaphandle kwesazi yokulayisha. Ukuba eso sifo sihlala sisasebenza, umthamo we 300 mg ungacingwa. I-psoriasis ye-plaque, i-dose ephakanyisiweyo i-300 mg kwiiveki 0, 1, 2, 3, 4 kunye neveki ezine emva koko. I-dose ephantsi ye-150 mg inokwanela kwabanye abantu. Kubantu abanesifo se-psoriatic ne-psqueasis ye-plaque, umgaqo-nkqubo we-psoriasis we-plaque unconyiswa.
Ngubani Akufanele Asebenzise I-Cosentyx?
Abantu abaye bafumana isifo esibi kakhulu kwi-secukinumab akufanele basebenzise amayeza.
Iziphumo eziPhakathi
Iziphumo eziqhelekileyo ezichaphazelekayo ezinxulumene neCosentyx ziquka i-nasopharyngitis (iimpawu ezibandayo), izifo eziphezulu zokuphefumla, kunye nesifo sohudo. Ezinye iziphumo zempembelelo ziyakwenzeka kwaye ukuba unamava okukhathazayo, qhagamshelana nogqirha wakho.
Izilumkiso kunye nokuqapha
Ezinye izilumkiso kunye nezilumkiso zidibene neCosentyx:
- Izifo ezithintekayo zenzeke ngokusetyenziswa kwayo. Ngenxa yokuba i-Cosentyx yenza kwi-immune system, inokunciphisa amandla akho okulwa nezifo kwaye inokunyusa ingozi yokusuleleka. Ukuba usulelo olusakhulayo luyaqhubeka ngenkathi usebenzisa i-Cosentyx, unqamle unyango xa unyango luphathwa. Enyanisweni, abantu abaneentsholongwane zangoku, ukusuleleka kwintsholongwane engapheliyo, okanye imbali yezifo ezithintekayo kufuneka baqaphele baze baxoxe ngembali yabo yesifo kunye nodokotela wabo ngaphambi kokusebenzisa i-Cosentyx.
- Ngaphambi kokuqala unyango kunye neCosentyx, kufuneka uhlolwe isifo sofuba . Ukuba ugqirha wakho uziva usemngciphekweni wesifo sofuba ngenxa yokuba utyhilekile, unako ukuphathwa nge-TB ngaphambi kokuba uqalise i-Cosentyx kwaye xa uphathwa nge-Cosentyx.
- Kwizilingo zekliniki, iziganeko ezitsha zokuqala zezifo zesibindi ziphawulwe, kunye nokunyanzeliswa kwabo baqhube ne-IBD. Iseluleko kufuneka sisetyenziswe xa i-Cosentyx imiselwe umntu ono-IBD owaziwayo.
- I-Anaphylactic okanye ingxaki enkulu yokuziphendulela inokwenzeka. Ukuba kwenzeka, i-Cosentyx kufuneka isuswe ngokukhawuleza kwaye kufuneka ufune uncedo lwezokwelapha.
- Iigciwane lokuphila kufuneka unganikiweyo, ukuba usebenzisa i-Cosentyx.
- Akukho zifundo ezaneleyo ze-Cosentyx kwabasetyhini abakhulelweyo. Kwakungaziwa nokuba ngaba i-Cosentyx ixutywe ebisi lomntu okanye ichithwe inkqubo emva kokutya. Ilumkiso kufuneka lisetyenziswe.
ILizwi
Njengoko siyazi, iziyobisi azisebenzisi ngokulinganayo kubo bonke abantu abazama. Yingakho kubalulekile ukuba ube neendlela ezininzi zokonyango. Ukususela kwi-Cosentyx yipilisi yokuqala ukujolisa kwe-interleukin-17A, indlela yonyango ifumaneka ngoku ayizange ifumaneke phambi kokuba kuvunywe iziyobisi.
Ukusebenzisa i-Cosentyx ngokukhuselekileyo, kufuneka ufunde indlela yokuyila ngokufanelekileyo, uqaphele iziphumo ezichaphazelekayo kunye nezilumkiso, kwaye uchaze nayiphi na imiphumo emibi xa ivela. Ukuba unomdla wokufunda okungakumbi malunga nalo khetho, yizise kule nkcazo yezempilo. Uya kuhamba nawe ukuya kwisigqibo esiphezulu kuwe.
Imithombo:
Cosentyx. Ulwaziso loLwazi . Novartis Pharmaceuticals Corporation. UJanuwari uhlaziywe ngo-2016.
Cosentyx. Guide Guide . Novartis Pharmaceuticals Corporation. UJanuwari uhlaziywe ngo-2016.